Myriad Genetics stock direction hangs on psychiatric debate, Barron’s says

Many people suffering from depression are not helped by their first drug treatment, with genetics accounting for some of this treatment resistance, Bill Alpert writes in this week’s edition of Barron’s. Whether there is enough knowledge about genes to help depressed patients is a fierce debate among psychiatrists and Wall Street analysts, and one that can be tracked via Myriad Genetics’ stock, he adds. With business getting competitive of late, Myriad is pinning its hopes on new tests and none is more important than GeneSight, which analyzes genes associated with antidepressant drugs’ effectiveness, then guides doctors in the choice of treatments, the publication explained. Unfortunately, the pivotal trial aimed at establishing GeneSight as a standard of care yielded mixed results and hasn’t settled the debate or lifted the stock, Alpert notes.
https://thefly.com/landingPageNews.php?id=2862055